about
Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entityReliability, validity and clinical correlates of the Quality of Life in Alzheimer’s disease (QoL-AD) scale in medical inpatientsComparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up studyDiagnosis and management of dementia with Lewy bodies: third report of the DLB ConsortiumDysphagia in Lewy body dementia - a clinical observational study of swallowing function by videofluoroscopic examination.A Diagnostic Model for Dementia in Clinical Practice-Case Methodology Assisting Dementia Diagnosis.Kynurenic Acid levels in cerebrospinal fluid from patients with Alzheimer's disease or dementia with lewy bodies.Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's diseaseTreatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective studyEfficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment.Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease.A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease.Cognitive impairment is undetected in medical inpatients: a study of mortality and recognition amongst healthcare professionals.The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson's disease with dementia.Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies.Solitary living in Alzheimer's disease over 3 years: association between cognitive and functional impairment and community-based services.Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease.Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's disease with common cognitive tests.Predictors of long-term cognitive outcome in Alzheimer's diseaseMedial temporal lobe atrophy is underreported and may have important clinical correlates in medical inpatients.Increased CSF biomarkers of angiogenesis in Parkinson diseaseCholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer's disease: a prospective, observational study of factors affecting survival time from admission to death.Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patientsA new automated method for analysis of rCBF-SPECT images based on the active-shape algorithm: normal values.A longitudinal study of physical function in patients with early-onset dementia.Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases.Patients with Lewy body dementia use more resources than those with Alzheimer's disease.A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.Multidisciplinary intervention reducing readmissions in medical inpatients: a prospective, non-randomized study.Longitudinal study of CSF biomarkers in patients with Alzheimer's disease.Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical CorrelatesAlzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort.Risk factors that affect life expectancy in Alzheimer's disease: a 15-year follow-up.Gender-dependent levels of hyaluronic acid in cerebrospinal fluid of patients with neurodegenerative dementia.Effects of carbonated liquid on swallowing dysfunction in dementia with Lewy bodies and Parkinson's disease dementia.Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.
P50
Q22251370-1CC626BB-A560-40D5-AE0E-C00DDD240A4AQ24658417-0C783F71-4892-4E65-AAB8-3F8853CB53A2Q28728080-AF8DB18D-4758-4945-95C7-3E85CCF2BE49Q29614409-8EB0B37A-3127-41C3-8099-93CE07DACD89Q31141124-DEF8F8C2-56D3-4DDD-A8B0-5604D11F6C0DQ33362485-FAF48F4D-1E89-4B78-A4E8-DE56002427D3Q33572850-F06B7D35-51BB-4B0A-8640-9BD19CE4DDBDQ33822641-A04E2722-9D93-4810-94C5-4E21419507C5Q33879213-5815165E-55DB-4A39-968A-FC4A98F459F9Q34128361-3DDA3809-0886-43EF-84DA-7842B86FB720Q34233759-E1F3A800-F9B0-4ED6-AFB6-99D7DF3684ECQ34318028-691DDE90-4365-4964-91BE-3497E25B8732Q34392848-2501E17A-4920-4440-90A7-F209531067AEQ34437544-2E4E9D9F-A7F0-4A3A-9467-85B11A6E8A06Q34463167-B91D9A2E-F799-46E5-AC3F-D042E14EAD48Q34548336-91E6E050-D461-4C24-B4F8-40ECFF0F42A6Q34779254-193D4F23-402B-45B9-8626-04081A2A6FF1Q34807142-BA752735-61F2-4B44-A4EC-5F32D448E5CFQ34974315-850FA0D2-E554-472C-A6E5-86E6BA71435CQ35579243-86BB4B71-B49F-46FE-9D50-8275F8C026F7Q35664424-D2DB46F0-D7F7-43E3-BBC4-82563FF443F7Q35825166-4A27108C-27E8-433F-974D-B6A8590A9146Q36118948-02D883DC-2915-4865-B40F-ECE36A38C901Q36120659-C8B841B8-771C-4890-AE2C-7C13FD7D8FB0Q36230306-11BAFC86-17DA-46DA-9ABA-0B1C73AB0302Q36551480-B1639D06-D3F3-4156-9825-3C44948F810FQ36595652-7869E3E0-FD2F-4B67-8F19-66546D29BA13Q36694930-98DB2C45-778F-4C68-BE2B-566656282DAEQ36723409-287E48BE-37E8-44FA-8646-BEF4526C6889Q37219010-2F2F2839-0A21-4BB4-ABA1-D06D84ACB1FCQ37254705-0AF9F166-9032-4A22-ABED-9A8F6746C4AAQ38585712-E69D9CAB-2154-49C0-AEFC-7A25A42F6859Q38853776-58293A3C-C3CF-4B35-B538-94F10427EE22Q38901561-606AFB76-0635-4DA1-940A-54E0DAD9B40FQ39165141-C88C3EE9-6163-4AD9-B8CE-F964D242E579Q39672969-41359D2E-A358-46EE-808D-DC79E2465DEDQ40076815-1112AFD2-859F-4E05-8A50-91FAA1593CCFQ40118493-665BFDA8-AA5C-401A-BB0E-CB9881AF4384Q40349700-7EB5DF5B-4A6D-4C13-8DDD-3E65DBEF4793Q40604774-9FDD1D71-9F39-4555-91C1-0770367D0931
P50
name
Elisabet Londos
@ast
Elisabet Londos
@en
Elisabet Londos
@nl
type
label
Elisabet Londos
@ast
Elisabet Londos
@en
Elisabet Londos
@nl
prefLabel
Elisabet Londos
@ast
Elisabet Londos
@en
Elisabet Londos
@nl